This research and development of MenB meningococcal vaccines includes two technical routes: outer membrane vesicle (OMV) vaccines and recombinant protein vaccines. This article intends to review the development, production and application of MenB meningococcal OMV vaccines in order to provide a reference for the development of MenB meningococcal OMV vaccine in China.
Antigens, Bacterial ; Humans ; Meningococcal Infections/prevention & control* ; Meningococcal Vaccines ; Neisseria meningitidis, Serogroup B ; Serogroup ; Vaccines, Synthetic

DNA, Bacterial ; genetics ; Humans ; Molecular Typing ; Neisseria meningitidis, Serogroup B ; classification ; genetics

PURPOSE: Neisseria meningitidis and Neisseria gonorrhoeae share between 80% and 90% of their genetic sequence. Meningococcal serogroup B vaccines based on outer membrane vesicles—such as VA-MENGOC-BC—could cross-protect against gonorrhea. The aim of this study was to analyze the incidence rates of gonorrhea and other sexually transmitted diseases with respect to the use of the VA-MENGOC-BC vaccine. MATERIALS AND METHODS: Health statistics between 1970 and 2017 were reviewed and the incidence of meningococcal disease and sexually transmitted diseases (gonorrhea, syphilis, condyloma acuminatum, hepatitis B and human immunodeficiency virus infection) were analyzed during the pre- and post-vaccination periods. Gonorrhea incidence was also analyzed by age groups. RESULTS: VA-MENGOC-BC was successfully used to control a meningococcal epidemic in Cuba. The strategy to combat the epidemic was carried out in two stages. The first one was a nationwide mass-vaccination campaign from 1989 to 1990, targeting the population at highest-risk aged 3 months to 24 years. During the second stage, begun in 1991, it was included in the Expanded Immunization Program. Gonorrhea incidence increased from 1970 to 1989. However, after the VA-MENGOC-BC massive vaccination campaign a sharp decrease of gonorrhea incidence was observed. It lasted between 1989 and 1993. A second incidence peak was detected in 1995, but it dropped again. Data clearly show a decline in the incidence of gonorrhea following massive vaccination, in contrast with other sexually transmitted diseases. Incidence rates in unvaccinated age groups also decreased, probably due to herd immunity. CONCLUSION: There is evidence that VA-MENGOC-BC could induce a moderate protection against gonorrhea.
Cuba ; Gonorrhea ; Hepatitis B ; HIV ; Humans ; Immunity, Herd ; Immunization Programs ; Incidence ; Membranes ; Neisseria gonorrhoeae ; Neisseria meningitidis ; Serogroup ; Sexually Transmitted Diseases ; Syphilis ; Vaccination ; Vaccines

Anti-Bacterial Agents ; pharmacology ; Bacterial Outer Membrane Proteins ; Bacterial Typing Techniques ; Electrophoresis, Gel, Pulsed-Field ; Microbial Sensitivity Tests ; Neisseria meningitidis, Serogroup B ; classification ; drug effects ; genetics ; Phylogeny

The antigenic similarity between Neisseria meningitidis group B (NMGB) capsular polysaccharide (PS) and human polysialic acid (PSA) has hampered the development of a NMGB PS-based vaccine. But the possibility of a safe vaccine based on NMGB PS has been demonstrated by the existence of the NMGB PS-associated nonautoreactive epitope, which is distinct from those present on human PSA. To obtain peptide mimotopes of NMGB PS, we used HmenB3, a protective and nonautoreactive monoclonal antibody, to screen a phage library with 12 amino acids. We obtained 23 phage clones that bound to HmenB3 but not in the presence of E. coli K1 PS [which is alpha (2-8) -linked PSA like NMGB PS]. The clones contained 3 mimotopes and differed from previously described NMGB PS mimotopes. Immunization with a synthetic peptide of one mimotope elicited anti-NMGB antibodies in BALB/c mice. These mimotopes may be useful in the development of group B meningococcal vaccines.
Amino Acid Sequence ; Animals ; Bacterial Vaccines/*immunology ; Cloning, Molecular ; Female ; Meningococcal Infections/*immunology/*prevention & control ; Mice ; Mice, Inbred BALB C ; Molecular Sequence Data ; Neisseria meningitidis, Serogroup B/genetics/*immunology ; Polysaccharides, Bacterial/genetics/*immunology ; Research Support, Non-U.S. Gov't